rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide

Glioma Clinical Trial

Official title:

Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03687957
• Other study ID #: 201810185
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 4, 2019
• Est. completion date: January 31, 2032

Study information

• Verified date: January 2024
• Source: Washington University School of Medicine
• Contact: Milan Chheda, M.D.
• Phone: 314-747-2712
• Email: mchheda[@]wustl.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators have developed a phase I/II clinical trial to evaluate the effect of rhIL-7-hyFc on lymphocyte counts in patients with high grade glioma (HGG).

A phase I study will test whether rhIL-7-hyFc can be safely administered to patients with HGG. Six doses of rhIL-7-hyFc will be tested using a mix of Accelerated Phase and standard 3+3 dose-escalation design. The phase II portion to test effect of rhIL-7-hyFc on lymphocyte counts will use placebo-controlled randomization in HGG patients whose treatment include the standard radiation therapy (RT) and temozolomide (TMZ).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: January 31, 2032
• Est. primary completion date: January 31, 2032
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• World Health Organization (WHO) grade III, grade IV, and high risk grade II gliomas that require RT and TMZ treatment.

• Phase 2 Expansion Cohort ONLY: Must be IDH1 wildtype, as defined by negative immunohistochemistry using an R132H-specific antibody and MGMT promoter unmethylated glioblastoma multiforme (WHO grade IV).

• Post-operative treatment must have included radiation and TMZ. Prior Gliadel Wafers are allowed. Glucocorticoid therapy is allowed. Tumor treating fields (TTF) device is allowed.

• Adequate organ and marrow function defined as follows:

• Absolute neutrophil count = 1,000/mcL

• Platelets = 75,000/mcL

• Hemoglobin = 8 g/dL

• Total bilirubin = 3.0 x institutional upper limit of normal

• AST (SGOT)/ALT (SGPT) = 3.0 × institutional upper limit of normal

• Absolute lymphocyte count (ALC) = 600/mcL (required for phase I and randomized phase II only)

• Karnofsky Performance Status (KPS) = 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).

• Able to provide written informed consent (or consent from a legally authorized representative).

• Women of childbearing potential must have a negative serum pregnancy test prior to study entry (within 14 days). Patients must be willing to be on adequate contraception during treatment.

• 18 years of age.

Exclusion Criteria:

• Receiving any other investigational agents which may affect patient's lymphocyte counts.

• Pregnant women are excluded from this study because rhIL-7-hyFc has not been evaluated regarding its potential for teratogenic or abortifacients effects. There is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drug, breastfeeding should be discontinued if the mother is treated with rhIL-7-hyFc.

• Has an active viral infection requiring systemic treatment at screening.

• Has active autoimmune disease or syndrome (i.e. moderate or severe rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, myasthenia gravis, Guillain Barre syndrome, systemic lupus erythematosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's etc.,) that requires systemic treatment at the time of screening. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Subjects are permitted to enroll if they have vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.

• Receipt of live attenuated vaccine within 30 days before the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), Zoster, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed.

• Has clinically significant cardiac enzymes ([Tnl or TnT] or CK-MD)

• Patients with a clinically significant EKG on screening triggering a echocardiogram which is also clinically significant

Related Conditions & MeSH terms

• Glioma

Intervention

Drug:
• rhIL-7-hyFc
-Given by intramuscular injection
• Placebo
-Given by intramuscular injection
• Temozolomide
-Standard of care

Radiation:
• Radiation therapy
-Standard of care

Procedure:
• Blood sample
Week 1 (prior to the 1st dose of rhIL-7-hyFc) Week 2 (one week after rhIL-7-hyFc) Week 3 (two weeks after rhIL-7-hyFc) Week 4 (three weeks after rhIL-7-hyFc) Week 13 (prior to the 2nd dose of rhIL-7-hyFc) Week 14 (one week after rhIL-7-hyFc) Week 16 (three weeks after rhIL-7-hyFc) - optional Week 45 (eight weeks after the last dose of rhIL-7-hyFC) If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level At the time of tumor progression

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (3)

Lead Sponsor	Collaborator
Washington University School of Medicine	NeoImmuneTech, The Foundation for Barnes-Jewish Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: Safety and tolerability of rhIL-7-hyFc as measured by the maximum tolerated dose (MTD) - Phase I only	-The maximum tolerated dose (MTD) is defined as the dose level immediately below the non-tolerated dose. A total of at least 6 patients must be treated at a dose level for it to be considered the MTD.	Completion of enrollment of phase I portion of study (estimated to be 1 year)
Primary	Phase I: Safety and tolerability of rhIL-7-hyFc as measured by dose-limiting toxicities (DLTs)	-DLT will be defined as = grade 3 non-dermatological and non-hematological AEs that occur within 30 days from the date when patients receive the 1st dose of rhIL-7-hyFc administration and are concluded to be possibly, likely or definitely related to the drug regimen that occurs during cycle 1, with severity graded according to the Common Terminology Criteria for Adverse Events (CTCAE) 5.0.	30 days from the date when patients receive the 1st dose of rhIL-7-hyFc administration (estimated to be 29 weeks)
Primary	Randomized Phase II: Percent increase of absolute lymphocyte count		Prior to adjuvant TMZ (approximately week 4)
Primary	Phase II Expansion Cohort: Progression-free survival (PFS)	-Defined from date of surgery to date of progression or death due to disease or date of last clinical follow up.	Through completion of follow-up (estimated to be 5 years and 6 months)
Secondary	Phase I and Randomized Phase II: Immunogenicity as measured by anti-drug antibodies	-The formation of anti-drug antibodies (ADA) to rhIL-7-hyFc will be evaluated: BioAgilytix will perform both Elisa Binding (non-neutralizing) and neutralizing antibody assays according to their Standard Operating Procedure.	Baseline through Week 14
Secondary	Phase I: Absolute lymphocyte count (ALC)		1 year
Secondary	Phase I and Randomized Phase II: Immunogenicity as measured by neutralizing anti-drug antibodies	-The formation of neutralizing anti-drug antibodies (NADA) to rhIL-7-hyFc will be evaluated: BioAgilytix will perform both Elisa Binding (non-neutralizing) and neutralizing antibody assays according to their Standard Operating Procedure.	Baseline through Week 14

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine